We are live on ! Find out more
PHS

PFM Health Sciences Portfolio holdings

AUM $1.1B
1-Year Est. Return 57.92%
This Fund
S&P 500
This Quarter Est. Return
+9.18%
1 Year Est. Return
+57.92%
3 Year Est. Return
+183.93%
5 Year Est. Return
+283%
10 Year Est. Return
+2,507.28%
AUM
$1.17B
AUM Growth
-$203M
Cap. Flow
-$271M
Cap. Flow %
-23.1%
Top 10 Hldgs %
53.52%
Holding
83
New
18
Increased
13
Reduced
24
Closed
26

Top Buys

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$20M
2
NTRA icon
Natera
NTRA
+$15.8M
3
COR icon
Cencora
COR
+$15.4M
4
MASI
Masimo
MASI
+$15.1M
5
ARQT icon
Arcutis Biotherapeutics
ARQT
+$12.9M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$61.6M
2
ABBV icon
AbbVie
ABBV
+$54.1M
3
ELV icon
Elevance Health
ELV
+$38.4M
4
ARGX icon
argenx
ARGX
+$35.8M
5
UHS icon
Universal Health Services
UHS
+$29.2M

Sector Composition

Rank Sector Weight
1 Healthcare 94.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LLY icon
1
Eli Lilly
LLY
$1.04T
$209M 17.79%
268,023
-5,755
-2% -$4.47M
THC icon
2
Tenet Healthcare
THC
$17B
$87.9M 7.48%
499,243
+7,909
+2% +$1.19M
MCK icon
3
McKesson
MCK
$96.6B
$53M 4.51%
72,313
-25,185
-26% -$17.8M
AXSM icon
4
Axsome Therapeutics
AXSM
$12.3B
$50.4M 4.29%
483,105
-73,440
-13% -$7.78M
ISRG icon
5
Intuitive Surgical
ISRG
$121B
$48.3M 4.12%
88,967
-4,106
-4% -$2.15M
PEN icon
6
Penumbra
PEN
$12.5B
$42.7M 3.63%
166,261
– –
ASND icon
7
Ascendis Pharma A/S
ASND
$16.6B
$38.3M 3.26%
221,754
+34,838
+19% +$5.67M
SLNO
8
DELISTED
Soleno Therapeutics
SLNO
$34.1M 2.9%
407,202
-188,004
-32% -$14.1M
CVS icon
9
CVS Health
CVS
$139B
$33M 2.81%
479,005
+166,700
+53% +$10.9M
OM icon
10
Outset Medical
OM
$77.5M
$32M 2.72%
1,664,727
-21,000
-1% -$328K
DHR icon
11
Danaher
DHR
$125B
$31.9M 2.71%
161,413
+48,938
+44% +$9.49M
EW icon
12
Edwards Lifesciences
EW
$48.5B
$30.7M 2.61%
392,503
+12,549
+3% +$936K
HCA icon
13
HCA Healthcare
HCA
$82.9B
$27.7M 2.36%
72,290
-5,174
-7% -$1.86M
HUM icon
14
Humana
HUM
$48B
$26.8M 2.28%
109,511
+46,273
+73% +$11.5M
MOH icon
15
Molina Healthcare
MOH
$11.7B
$25.5M 2.17%
85,739
+15,651
+22% +$4.91M
ALNY icon
16
Alnylam Pharmaceuticals
ALNY
$35.4B
$23.6M 2%
72,220
-14,925
-17% -$4.13M
BBIO icon
17
BridgeBio Pharma
BBIO
$16.1B
$22.5M 1.92%
521,793
-386,342
-43% -$14.1M
TEVA icon
18
Teva Pharmaceuticals
TEVA
$35.6B
$20.8M 1.77%
+1,238,846
New +$20M
UNH icon
19
PUT
UnitedHealth
UNH
$394B
$20.3M 1.73%
+65,000
New +$24.8M
INDV icon
20
Indivior Pharmaceuticals
INDV
$4.75B
$20M 1.7%
1,355,931
+196,098
+17% +$2.28M
NTRA icon
21
Natera
NTRA
$37.8B
$17.1M 1.46%
+101,250
New +$15.8M
COR icon
22
Cencora
COR
$59.1B
$16M 1.36%
+53,287
New +$15.4M
MASI
23
DELISTED
Masimo
MASI
$15.9M 1.35%
+94,451
New +$15.1M
OSCR icon
24
Oscar Health
OSCR
$9.11B
$15.8M 1.34%
735,033
-125,788
-15% -$1.87M
WAT icon
25
Waters Corp
WAT
$36.4B
$15M 1.28%
43,089
-8,769
-17% -$3.01M
1
2 3 4

Similar funds

DAM
Delta Asset Management Memphis, Tennessee $1.1B AUM 14.89% 1-Year Est. Return
MAM
Mark Asset Management New York $1.1B AUM 43.79% 1-Year Est. Return
CPRC
Consolidated Portfolio Review Corp Woodbury, New York $1.1B AUM 8.96% 1-Year Est. Return
LCM
Legato Capital Management San Francisco, California $1.1B AUM 61.65% 1-Year Est. Return
PRS
Pinkerton Retirement Specialists Coeur D Alene, Idaho $1.1B AUM 30.57% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return
CF
Corebridge Financial Houston, Texas $1.09B AUM 1.85% 1-Year Est. Return

PFM Health Sciences's Q2 2025 Portfolio in Review

As of Q2 2025, PFM Health Sciences held 83 positions worth $1.17B, down 15% from $1.38B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

PFM Health Sciences withdrew a net $271M in Q2 2025, closing 26 positions and reducing 24 holdings. Its most notable exit was Vertex Pharmaceuticals, an estimated $61.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 92% a quarter earlier.

Against the trend, PFM Health Sciences opened a new position in Teva Pharmaceuticals worth $20.8M.

  • PFM Health Sciences's largest Q2 2025 buy was Teva Pharmaceuticals: 1,238,846 shares worth $20.8M.
  • PFM Health Sciences added most to Humana in Q2 2025, an estimated $11.5M increase.
  • PFM Health Sciences's biggest Q2 2025 reduction was AbbVie, cutting an estimated $54.1M.
  • PFM Health Sciences fully exited Vertex Pharmaceuticals in Q2 2025, selling an estimated $61.6M.
  • PFM Health Sciences's ten largest holdings make up 54% of its $1.17B portfolio in Q2 2025.
  • PFM Health Sciences opened 18 new positions and closed 26 in Q2 2025.
  • PFM Health Sciences's portfolio value fell 15% quarter-over-quarter to $1.17B.

Based on PFM Health Sciences's 13F filing for Q2 2025, filed 14 Aug 2025.